News

FDA Grants Breakthrough Therapy Status to Kowa’s K-808 for Rare Liver Disease

Kowa’s selective PPARα modulator “K-808” (pemafibrate) has been granted “breakthrough therapy” designation by the US FDA for the treatment of primary biliary cholangitis.